What is the revenue and EPS growth rate for Clover Health year over year?

What guidance did Clover Health's management provide for the next earnings period?

What were the key takeaways from Clover Health's earnings call?

What is Clover Health's gross profit margin?

What is Clover Health's latest dividend and current dividend yield?

What is the market's earnings forecast for Clover Health next quarter?

What factors drove the changes in Clover Health's revenue and profit?

Did Clover Health beat or miss consensus estimates last quarter?

- **Revenue Surge**: 35% membership growth to 109,000, revenue up 49% YoY to $479M.
- **Profitability Challenges**: $45M adjusted EBITDA (down $17M YoY) due to 44,000 new members and 4% medical cost trend.
- **Star Rating Update**: 3.5-star for 2026,4-star target with CMS rate benefits.
- **2026 Outlook**: 90-91% BER, $15-30M EBITDA,2026, 17-18% SG&A leverage.

**【CEO Summary Section】**
- **Revenue Growth**: 35% year-over-year membership growth to 109,000 members, with insurance revenue up 49% YoY to $479 million.
- **Adjusted EBITDA Pressure**: Missed 2025 targets due to higher-than-expected new member growth (44,000 gross new members) and utilization challenges, resulting in $45 million year-to-date adjusted EBITDA (down $17 million YoY).
- **Clover Assistant Impact**: Returning members generate $217/month contribution profit, while new members incur $110/month loss. Year 3+ cohorts show 1,400 basis point MCR improvement.
- **Star Ratings**: 3.5-star rating for 2026, aiming for 4-star in 2026 with CMS rate updates and Part D subsidies.

**【CFO Financial Commentary】**
- **Medical Cost Trends**: 4% YoY increase (excluding pharmacy), with elevated inpatient, oncology, and DME claims.
- **Profitability**: Positive adjusted EBITDA and net income ($45M and $44M YoY), despite $12 million operating cash flow.
- **2025 Guidance**: Updated to $1.85-1.88 billion revenue, $15-30 million adjusted EBITDA, and 90-91% BER.
- **2026 Outlook**: Stronger returning member cohorts, 4-star payment year, and $325-335 million SG&A (17-18% of revenue).

CLOV

CLOV fundamentals

You can ask Aime